BioSpace News Archive

Sensient Technologies Corporation reported consolidated revenue of $323.6 million in this year’s third quarter compared to $317.7 million in last year’s third quarter.

Prospective, multi-center study data support use of DecisionDx®-Melanoma in T1-T2 melanoma patients 65 years and older to identify those with a low probability of sentinel lymph node positivity

-- If Approved, KTE-X19 will be an Important New Advance for this Disease with a Poor Prognosis -- -- Kite would Become the First Company with Multiple Approved CAR T Therapies in Europe -- SANTA MONICA, Calif.--( BUSINESS WIRE )-- Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company’s Marketing Auth

Effective October 5, 2020, DDS Lab has appointed Bart J. Doedens as its new CEO.

Beyond Air, Inc. (NASDAQ: XAIR), today announced new in vitro and in vivo preclinical data that suggest the Company’s innovative gNO-based treatment may treat lung cancer

- Oral presentation of positive phase 2 results from a study of fosmanogepix in candidemia to be presented at IDWeek 2020 - First preclinical and clinical data on anti-BKV monoclonal antibody MAU868 to be presented at Kidney Week 2020

Data presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right heart failure and early use of Impella RP is associated with significantly higher survival rates.

The data will be presented at the American College of Chest Physicians virtual CHEST Annual Meeting 2020 taking place October 18–21, 2020.

Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4 th Complement-based Drug Development Summit. OMS906 is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway. The presentation about the inhibition of the alternative pathway by targeting MASP-3 was made b

New executive brings over 20 years of experience serving as CFO for publicly-traded biopharmaceutical companies as Edgewise advances clinical muscular dystrophy program - BOULDER, Colo.--( BUSINESS WIRE )-- Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of R. Michael Carruthers to the newly created position of Chief Financial Officer